Completed PHASE3 INTERVENTIONAL NCT00574795

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants

A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Vaccines, Pneumococcal Conjugate Vaccine

Interventions 13vPnC

Updated 6 times since 2017 Last updated: Jun 28, 2012 Started: Sep 30, 2007 Primary completion: Aug 31, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Vaccines, Pneumococcal Conjugate Vaccine, this trial is completed. The trial is conducted by Wyeth is now a wholly owned subsidiary of Pfizer and has accumulated 6 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Asahikawa-shi, Japan , Chiba, Japan , Fukuoka, Japan , Ise-shi, Japan , Kurashiki-shi, Japan , Maebaru-shi, Japan , Matsuyama, Japan , Meguro-ku, Japan , Nagoya, Japan , Nangoku-shi, Japan and 7 more locations